2007
DOI: 10.1080/09595230701499118
|View full text |Cite
|
Sign up to set email alerts
|

Attitudes and beliefs towards methadone maintenance treatment among Australian prison health staff

Abstract: This is the first survey to examine prison health staff attitudes to methadone treatment. Correctional health staff tend to be more abstinence-orientated, more likely to disapprove of drug use, and less knowledgeable about the risks and benefits of methadone than Australian community methadone staff. The findings have important implications for training health staff working in the prison environment with regard to client retention on methadone treatment.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
16
0
4

Year Published

2010
2010
2022
2022

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 24 publications
(21 citation statements)
references
References 20 publications
(46 reference statements)
1
16
0
4
Order By: Relevance
“…The perception that WP-DI, though fraught with extraordinary risks is nevertheless inevitable, points to an imbalance in resources for HIV prevention and assets promoting drug use that perpetuates high-risk WP-DI and underpins prisoners' decisions about drug treatment and HIV care. Prison-based MMT has consistently been documented to reduce WP-DI and improve overall health with few negative consequences (Stallwitz and Stover, 2007) Yet, entrenched negative attitudes about MMT among prisoners (Bachireddy et al, 2011; Zamani et al, 2010), prison personnel (Gjersing et al, 2007; Polonsky et al, 2015) and family members (Liu et al, 2013), and fear of being ostracized by other prisoners still influence drug treatment decisions among opioid-dependent prisoners. Compounding these are concerns about “mixing” of methadone with life-preserving ART (Altice et al, 2001), which are in part accurate since most first-line ART in Indonesia includes a non-nucleoside reverse transcriptase inhibitor, which causes symptoms of withdrawal in a third to half of prisoners on methadone unless methadone doses are escalated soon after ART initiation (Altice et al, 2010; Gruber and McCance-Katz, 2010).…”
Section: Discussionmentioning
confidence: 99%
“…The perception that WP-DI, though fraught with extraordinary risks is nevertheless inevitable, points to an imbalance in resources for HIV prevention and assets promoting drug use that perpetuates high-risk WP-DI and underpins prisoners' decisions about drug treatment and HIV care. Prison-based MMT has consistently been documented to reduce WP-DI and improve overall health with few negative consequences (Stallwitz and Stover, 2007) Yet, entrenched negative attitudes about MMT among prisoners (Bachireddy et al, 2011; Zamani et al, 2010), prison personnel (Gjersing et al, 2007; Polonsky et al, 2015) and family members (Liu et al, 2013), and fear of being ostracized by other prisoners still influence drug treatment decisions among opioid-dependent prisoners. Compounding these are concerns about “mixing” of methadone with life-preserving ART (Altice et al, 2001), which are in part accurate since most first-line ART in Indonesia includes a non-nucleoside reverse transcriptase inhibitor, which causes symptoms of withdrawal in a third to half of prisoners on methadone unless methadone doses are escalated soon after ART initiation (Altice et al, 2010; Gruber and McCance-Katz, 2010).…”
Section: Discussionmentioning
confidence: 99%
“…In addition to diffusing information, training can help individuals to reconcile beliefs that an innovation, such as pharmacotherapy, is incompatible with the values of their profession (Marinelli-Casey, Domier, & Rawson, 2002). Criminal justice and corrections staff often have limited knowledge regarding addiction pharmacotherapy as well as negative attitudes toward this form of treatment (Lee & Rich, 2012; Rich, et al, 2005), but training has been previously shown to improve attitudes and knowledge (Gjersing, Butler, Caplehorn, Belcher, & Matthews, 2007; McMillan & Lapham, 2005). …”
Section: Methodsmentioning
confidence: 99%
“…naltrexone, acamprosate, and disulfiram (Abraham, Knudsen, Rieckmann, & Roman, 2013) and buprenorphine for the treatment of opioid dependence (Knudsen, Ducharme, & Roman, 2007; Knudsen, Ducharme, Roman, & Link, 2005); (3) an instrument to assess abstinence orientation and disapproval of drug use (Gjersing, et al, 2007); and (4) items to assess current and future intent to refer clients to pharmacotherapy (Varra & Hayes, 2007; Varra, Hayes, Roget, & Fisher, 2008). …”
Section: Methodsmentioning
confidence: 99%
“…There exists a poor understanding of opioid dependence as a chronic and recurring disease; some clinicians may feel that a hedonistic practice indicates a weakness of character [5,24]. Another widespread but mistaken belief involves the benefits of abstinence for drug users, which leads to the omission of maintenance therapy after detoxification, which in turn leads to reversion to opioid use [31]. In Her Majesty's Prison at Leeds, 43% of prisoners with an illicit opioid habit continued to acquire and use opioids even through the first days of imprisonment and completion of a detoxification regimen [32].…”
Section: Why Is Drug Treatment For Prisoners Not Yet Comparable To Thmentioning
confidence: 99%